New treatment tested for rare childhood Muscle-Weakening disease
NCT ID NCT05644561
Summary
This study is testing whether ravulizumab, an intravenous medication, can help control symptoms of generalized myasthenia gravis in children aged 6 to 18. Researchers will measure how the drug works in the body and whether it improves muscle strength and daily activities. The study involves 12 children who will receive the treatment and be monitored for 18 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90078, United States
-
Research Site
Boston, Massachusetts, 02115, United States
-
Research Site
Chapel Hill, North Carolina, 27514, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Milan, 20133, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Itabashi-ku, 173-0003, Japan
-
Research Site
Belgrade, 11000, Serbia
-
Research Site
Belgrade, 11070, Serbia
-
Research Site
Bern, 3010, Switzerland
Conditions
Explore the condition pages connected to this study.